Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System

被引：0
|
作者：
Moore, Kristin J. [1 ]
Engel-Nitz, Nicole M. [1 ]
McMahon, Peter [2 ]
Beal, Jason [2 ]
Jhaveri, Teraneh Z. [2 ]
Williamson, Mellissa [2 ]
Andrade, Katherine [1 ]
Landis, Christina [1 ]
Sadek, Islam [2 ]
Hogea, Cosmina [2 ]
机构：
[1] Optum, Eden Prairie, MN USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Woodman, Richard C.
    Adesanya, Afoluso Ronnee
    Azarnia, Nozar
    Parris, Matthew
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [32] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [33] PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROMA PHASE II, OPEN-LABEL STUDY.
    Laille, E.
    Xiao, Z.
    Du, X.
    Dong, Q.
    Songer, S.
    Beach, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81
  • [34] BEYOND HYPOMETHYLATING AGENTS (HMAS): TREATMENT OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) AFTER FIRST-LINE THERAPY (1LT) USING A UNITED STATES (US) ELECTRONIC MEDICAL RECORD (EMR)
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Seal, B.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    VALUE IN HEALTH, 2017, 20 (05) : A138 - A138
  • [35] NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
    Kotsianidis, I.
    Hatzimichael, E.
    Pappa, V.
    Galanopoulos, A.
    Kourakli, A.
    Diamantopoulos, P.
    Papageorgiou, S.
    Liapis, K.
    Papadopoulos, V.
    Papoutselis, M.
    Bouchla, A.
    Georgoulis, V.
    Vassilakopoulos, T.
    Solomou, E.
    Dimou, M.
    Vassilopoulos, G.
    Vardi, A.
    Papaioannou, M.
    Pontikoglou, C.
    Anagnostopoulos, A.
    Panayiotidis, P.
    Kontopidou, F.
    Harchalakis, N.
    Adamopoulos, N.
    Ximeri, M.
    Zikos, P.
    Megalakaki, A.
    Repousis, P.
    Kotsopoulou, M.
    Dryllis, G.
    Tsoukanas, D.
    Kyrtsonis, M. -C.
    Poulakidas, E.
    Bouronikou, E.
    Delimpasis, S.
    Mparmparousi, D.
    Papadaki, H.
    Vyniou, N. A.
    Symeonidis, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [36] The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
    Zeidan, Amer M.
    Al Ali, Najla H.
    Kharfan-Dabaja, Mohamed A.
    Padron, Eric
    Zhang, Ling
    Epling-Burnette, Pearlie K.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [37] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre C.
    Sekeres, Mikkael A.
    Westermann, Jorg
    Xiao, Zhijian
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Ma, Fei
    Kiertsman, Flavia
    Stegert, Mario
    Hertle, Sabine
    Fenaux, Pierre
    Santini, Valeria
    BLOOD, 2020, 136
  • [38] Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
    Hasegawa, Ken
    Wei, Andrew H.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Rajakumaraswamy, Nishanthan
    Iqbal, Shahed
    Chan, Rebecca J.
    Hu, Hao
    Tse, Preston
    Yan, Jiajun
    Zoratti, Michael J.
    Xie, Feng
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Pevonedistat (P) plus azacitidine (A) vs A alone in higher-risk myelodysplastic syndromes (HR-MDS): efficacy and safety results from study P-2001 (NCT02610777)
    Giagounidis, A.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Lopez, Font P.
    Zeidner, J. F.
    Campelo, Diez M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhou, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D., V
    Ades, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 30 - 30
  • [40] PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777)
    Santini, V.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J. F.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D. V.
    Ades, L.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 3
12345